{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T05:11:40Z","timestamp":1772946700569,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019650","name":"Vir Biotechnology Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Microbes and New Infections"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.nmni.2025.101620","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T15:11:30Z","timestamp":1754665890000},"page":"101620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-092X","authenticated-orcid":false,"given":"Isabel H.","family":"Gonzalez-Bocco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayven","family":"Frierson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola A.","family":"Reyes Curcio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres E.","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Lahoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios G.","family":"Moshovitis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Beluch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manu","family":"Balusu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Elizabeth","family":"Keleher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dougan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer H.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Nader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Aylott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah P.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Manne-Goehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmni.2025.101620_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.nmni.2025.101620_bib2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2025.101620_bib3","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2025.101620_bib4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3390\/vaccines9060582","article-title":"Efficacy and safety of COVID-19 vaccines in phase III trials: a meta-analysis","volume":"9","author":"Cheng","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.nmni.2025.101620_bib5","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.nmni.2025.101620_bib6","series-title":"Severe outcomes among patients with coronavirus disease 2019 (COVID-19)","year":"2020"},{"key":"10.1016\/j.nmni.2025.101620_bib7","article-title":"Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients","author":"Agha","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.nmni.2025.101620_bib8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nmni.2025.101620_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.nmni.2025.101620_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40814-023-01325-y","article-title":"Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity","volume":"9","author":"Gonzalez-Bocco","year":"2023","journal-title":"Pilot Feasibility Stud"},{"key":"10.1016\/j.nmni.2025.101620_bib11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2025.101620_bib12","doi-asserted-by":"crossref","first-page":"1173.e1","DOI":"10.1016\/j.cmi.2021.04.028","article-title":"Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study","volume":"27","author":"Rozen-Zvi","year":"2021","journal-title":"Clin Microbiol Infection"},{"key":"10.1016\/j.nmni.2025.101620_bib13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients","volume":"385","author":"Hall","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2025.101620_bib14","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","article-title":"Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer","volume":"39","author":"Addeo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nmni.2025.101620_bib15","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.nmni.2025.101620_bib16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nmni.2025.101620_bib17","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1001\/jamaoncol.2021.4381","article-title":"Antibody response to COVID-19 vaccination in adults with hematologic malignant disease","volume":"7","author":"Ollila","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.nmni.2025.101620_bib18","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.nmni.2025.101620_bib19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ccell.2021.08.001","article-title":"Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer","volume":"39","author":"Mairhofer","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nmni.2025.101620_bib20","series-title":"Underlying medical conditions associated with higher risk for severe COVID-19: information for Healthcare Providers","year":"2021"},{"key":"10.1016\/j.nmni.2025.101620_bib21","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2025.101620_bib22","article-title":"GSK sotrovimab fact sheet for healthcare providers: emergency use authorization for sotrovimab","year":"2022","journal-title":"GSK"},{"key":"10.1016\/j.nmni.2025.101620_bib23","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2025.101620_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39292-w","article-title":"Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration","volume":"14","author":"Follmann","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.nmni.2025.101620_bib25","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and Cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2025.101620_bib26","article-title":"Table for grading the severity of adult and pediatric adverse events, corrected version 2.1. US department of health and human services, national institutes of health","year":"2017","journal-title":"National Institute Allergy Infect Dis Division AIDS"},{"key":"10.1016\/j.nmni.2025.101620_bib27","author":"Sinha","year":"2023","journal-title":"Safe Effect Use Baricitinib Remdesivir Hospital Patients Coronavirus (COVID-19)"},{"key":"10.1016\/j.nmni.2025.101620_bib28","series-title":"36-Item Short Form Survey (SF-36)","year":"2021"},{"key":"10.1016\/j.nmni.2025.101620_bib29","series-title":"FDA Updates sotrovimab emergency Use Authorization","article-title":"FDA limits use of Sotrovimab to treat COVID-19 in some U.S. regions due to the BA.2 Omicron sub-variant","year":"2022"},{"key":"10.1016\/j.nmni.2025.101620_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae236","article-title":"The effect of gastrointestinal graft-versus-host disease and diarrhea on the pharmacokinetic profile of sotrovimab in hematopoietic stem cell transplant recipients","author":"Boonyaratanakornkit","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nmni.2025.101620_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2420","article-title":"Efficacy and safety of tixagevimab\u2010cilgavimab as pre\u2010exposure prophylaxis for COVID\u201019: a systematic review and meta\u2010analysis","volume":"33","author":"Soeroto","year":"2023","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.nmni.2025.101620_bib32","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/M22-3428","article-title":"Safety and efficacy of combination SARS-CoV-2 neutralizing monoclonal antibodies Amubarvimab plus Romlusevimab in Nonhospitalized patients with COVID-19","volume":"176","author":"Evering","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nmni.2025.101620_bib33","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(21)00751-9","article-title":"Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial","volume":"22","author":"Self","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.nmni.2025.101620_bib34","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["New Microbes and New Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297525000599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297525000599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:58:55Z","timestamp":1772895535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2052297525000599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"alternative-id":["S2052297525000599"],"URL":"https:\/\/doi.org\/10.1016\/j.nmni.2025.101620","relation":{},"ISSN":["2052-2975"],"issn-type":[{"value":"2052-2975","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity","name":"articletitle","label":"Article Title"},{"value":"New Microbes and New Infections","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmni.2025.101620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101620"}}